Proteins binding bcma, nkg2d and cd16
AssigneeDragonfly Therapeutics, Inc.
InventorsGregory P. CHANG, Ann F. CHEUNG, William HANEY, Bradley M. LUNDE, Bianka PRINZ
Life of this patent
Estimating the term…
Abstract
Multi-specific binding proteins that bind BCMA, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Claims36
A protein comprising:
- (a) a first antigen-binding site that binds NKG2D;
- (b) a second antigen-binding site that binds BCMA;
- and
- (c) an antibody Fc domain or a portion thereof sufficient to bind CD16, or a third antigen-binding site that binds CD16.
A protein according to any one of the preceding claims, wherein the first antigen-binding site comprises a heavy chain variable domain at least 90% identical to SEQ ID NO:
- 1.
A protein according to any of the preceding claims, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:49 and the light chain variable domain of the second antigen-binding site comprises an amino acid sequence at least 90% identical to SEQ ID NO:53 or SEQ ID NO:54.
A protein according to any of the preceding claims, wherein the heavy chain variable domain of the second antigen-binding site comprises an amino acid sequence including:
- a heavy chain CDR1 sequence identical to the amino acid sequence of SEQ ID NO:50;
- a heavy chain CDR2 sequence identical to the amino acid sequence of SEQ ID NO:51;
- and
- a heavy chain CDR3 sequence identical to the amino acid sequence of SEQ ID NO:52.
A protein according to any one of the preceding claims, wherein the protein comprises a portion of an antibody Fc domain sufficient to bind CD16, wherein the antibody Fc domain comprises hinge and CH2 domains.
A formulation comprising a protein according to any one of the preceding claims and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.